20472 Federal Register / Vol. 65, No. 74 / Monday, April 17, 2000 / Notices

be required to receive copies of the

patent applications.

Imaging With Positron-Emitting

Taxanes as a Guide to Antitumor

Therapy

Jerry M. Collins, Raymond W. Klecker,

Lawrence Anderson (FDA)

Serial No. 60/155,061 filed 21 Sep 1999

The present application discloses the

use of positron-emitting compounds to

label taxane type drugs. This invention

also describes methods of synthesizing

these taxane type compounds. Further,

methods to guide treatment of solid

tumors, with labeled taxanes, are also

disclosed in the present application.

Advantages of using this technology

include: (1) Avoidance of exposing

patients to toxic drugs that have no

potential for benefit; (2) ability to

rapidly determine whether a given

tumor will be likely to respond to a

particular drug; and (3) the ability to

monitor the impact of various dosages,

schedules, and modulators for delivery,

in situ, at the actual tumor under

treatment conditions.

Conjugate Vaccine for Neisseria

Meningitidis

Xin-Xing Gu (NIDCD) and Chao-Ming

Tsai (FDA)

Serial No. 60/148,021 filed 10 Aug 1999

The invention discloses a vaccine

which comprises lipooligosaccharide

(LOS) isolated from N. meningitidis and

conjugated to a carrier protein. The

invention also discloses a method of

making the acellular vaccine. The

method consists of two main steps. In

the first step the lipooligosaccharide

(LOS), chosen so it does not contain the

lacto-N-neotetraose human antigen

(LNnT), is detoxified by a novel

procedure which uses hydrazine to

remove the O-linked fatty acids. In the

second step, the detoxified LOS (dLOS)

is covalently conjugated to a carrier

protein such as Tetanus Toxoid (TT).

The dLOS produced in step 1 is 10,000

fold less toxic than the parent LOS. The

conjugate vaccine exhibited a high level

of immunogenicity as evidenced by the

high titer of IgG antibody to native LOS,

obtained in mice and rabbits. The rabbit

antisera produced by the conjugate

vaccine of one N.meningitidis strain

(strain 7880, A,L10) exhibited

bactericidal activity and cross reactivity

with heterologous N.meningitidis

strains. A conjugate vaccine made in

this method may be multivalent,

composed of dLOSs from different

strains and/or immunotypes of N.

meningitidis and will thus protect

against all types of N. meningitidis,

including type B.

A portion of this invention was

disclosed in a poster by Tsai, Gu and

Quakyi at the Fifth Conference of the

International Endotoxin Society held in

Santa Fe, New Mexico in September 12–

15, 1998.

Dated: April 7, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–9444 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting John Peter Kim, at the Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 264; fax: 301/402–0220;

e-mail: jk141n@nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

High Speed Parallel Nucleic Acid

Sequencing

Thomas D. Schneider, Denise Rubens

(NCI)

Serial No. 60/151,580 filed 30 Aug 1999

The present application describes a

new method and apparatus for DNA

sequencing called Two Dye Sequencing

(TDS). This method employs engineered

DNA polymerases which are labeled

with a fluorophore such as Green

Fluorescent Protein (GFP) and are

combined with an annealed

oligonucleotide primer in a chamber of

a microscope field of view capable of

detecting individual molecules. Four

nucleotide triphosphates, each labeled

on the base with a different fluorescent

dye are introduced to the reaction. Light

of a specific wavelength is used to

excite the fluorophore on the

polymerase, which in turn excites the

neighboring fluorophore on the

nucleotide by Fluorescense Resonance

Energy Transfer (FRET). As nucleotides

are added to the primer, their spectral

emissions provide sequence information

of the DNA molecule.

Hydrazide Inhibitors of HIV–1

Integrase

Yves Pommier, Nouri Neamati, Zhaiwai

Lin, Terrence R. Burke, Jr. (NCI)

DHHS Reference Nos. E–037–99/0 filed

12 Mar 1999 and E–037–99/1 filed 10

Mar 2000

The human immunodeficiency virus

(HIV) is the causative agent of acquired

immunodeficiency syndrome (AIDS).

Drug-resistance is a critical factor

contributing to the gradual loss of

clinical benefit to treatments for HIV

infection. Accordingly, combination

therapies have further evolved to

address the mutating resistance of HIV.

However, there has been great concern

regarding the apparent growing

resistance of HIV strains to current

therapies.

It has been found that a certain class

of compounds including

salicylhydrazides and analogs and

derivatives thereof are effective and

selective anti-integrase inhibitors which

are active in the presence of both

Mn(+2) and Mg(+2) and which may be

used in the treatment or prevention of

infection by HIV and AIDS. The subject

invention provides for such compounds

and for methods of inhibiting HIV

integrase.

Dated: April 5, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–9446 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

‘‘Conference on Challenges in Health

Disparity in the New Millennium: A Call

to Action’’

Notice is hereby given of the NIH

Office of Research on Minority Health

(ORMH) Conference on Challenges in

Health Disparity in the New

Millennium: A Call to Action, which

will be held April 16–19, 2000, at the

Federal Register / Vol. 65, No. 74 / Monday, April 17, 2000 / Notices 20473

Hyatt Regency Washington on Capitol

Hill, 400 New Jersey Avenue, NW,

Washington, D. C. 20001. The

conference begins at 8:00 a.m. on April

17, 8:00 a.m. on April 18, and 8:30 a.m.

on April 19.

The Office of Research on Minority

Health (ORMH), Office of the Director,

National Institutes of Health (NIH), is

convening this conference. ORMH is a

central leadership entity at the NIH for

issues related to minority health

research and research training. Reports

of progress and accomplishments since

the founding of ORMH in 1990 and

developing a strategic plan for future

actions for eliminating health research

and research training disparities

comprise the agenda of the conference.

Specific conference objectives

include:

• Recommending a framework for the

ORMH to address continuing disparity

in health status of the US population

and the international community

through the Minority Health Strategic

Plan;

• Highlighting the role of the ORMH

to address disparity in health status

through basic and clinical research and

research training in biomedical and

behavioral sciences; and

• Promoting partnerships with

leaders in Congress, associations,

academic institutions, industry,

community-based organizations, and

other Federal agencies to help eliminate

health disparity.

The primary sponsor of this

conference is ORMH. Advance

information on the conference program

and conference registration materials

maybe obtained from Debra Rainey,

LCLM, LLC, Inc., 1299 Lamberton Drive,

Suite 205, Silver Spring, Maryland

20902 (telephone: 301–593–2800).

Dated: April 7, 2000.

Yvonne Maddox,

Acting Deputy Director, National Institutes

of Health.

[FR Doc. 00–9445 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary &

Alternative Medicine; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Cancer Advisory Panel for

Complementary and Alternative

Medicine.

The meeting will be closed to the

public in accordance with the

provisions set forth in section

552b(c)(9)(B), Title 5 U.S.C., as amended

because the premature disclosure of

program documents—PAC and the

discussions would likely to significantly

frustrate implementation of

recommendations.

Name of Committee: Cancer Advisory

Panel for Complementary and Alternative

Medicine.

Date: April 19, 2000.

Time: 2:30 PM to 5:00 PM.

Agenda: To review and evaluate the

Gonzalez Regiment.

Place: National Institutes of Health, 9000

Rockville Pike, Bldg. 31, Room 5B5B,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Richard Nahin, PhD,

Executive Secretary, Cancer Advisory Panel

for Complementary, and Alternative

Medicine, NCCAM, NIH, 9000 Rockville

Pike, Building 31, Room 5B37, Bethesda, MD

20892, 301–594–2013.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Dated: April 6, 2000.

Anna Snouffer,

Acting Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–9436 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 522b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel,

Mentored Clinical Scientist Development

Awards (K08).

Date: April 12, 2000.

Time: 2:30 PM to 4 PM.

Agenda: To review and evaluate grant

applications.

Place: 6701 Rockledge Drive, Room 7214,

Bethesda, MD 20892 (Telephone Conference

Call).

Contact Person: C. James Scheirer, PhD,

Chief, Review Branch, Division of Extramural

Affairs, National Heart, Lung, and Blood

Institute, Rockledge Center II, 6701

Rockledge Drive, Suite 7216, Bethesda, MD

20892–7924, 301–435–0266.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Disease Research; 93.839, Blood Diseases and

Resources Research, National Institutes of

Health, HHS)

Dated: April 6, 2000.

Anna Snouffer,

Acting Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–9434 Filed 4–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel

Fluorescent Indicator Dyes for Extracellular

Ions (SBIR).

Date: May 4, 2000.

Time: 9:00 AM to 11:00 AM.

Agenda: To review and evaluate contract

proposals.

Place: 6701 Rockledge Drive, Room 4212,

Bethesda, MD 20817 (Telephone Conference

Call).